Paper · 28303906

Advances and challenges in targeting FGFR signalling in cancer.

Babina IS and 1 other. Nat Rev Cancer, 2017. Cited by 670 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Advances and challenges in targeting FGFR signalling in cancer. Papers, record 28303906. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28303906

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Advances and challenges in targeting FGFR signalling in cancer.; PubMed
Journal: Nat Rev Cancer; PubMed
Year: 2017; PubMed
Publication types: Journal Article, Review, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/28303906/; PubMed
DOI: https://doi.org/10.1038/nrc.2017.8; PubMed
The journal: https://conductscience.org/library/journal-index/101124168; PubMed
Citations, by iCite: 670; iCite
Relative citation ratio, by iCite: 21.2; iCite
Revised in PubMed: 2022-04-08; PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	Kind	ORCID iD
1	Babina IS	Irina S
2	Turner NC	Nicholas C

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Neoplasms	Major topic
Receptors, Fibroblast Growth Factor	Major topic
Signal Transduction	Major topic
Animals
Antineoplastic Agents
Fibroblast Growth Factors
Humans
Molecular Targeted Therapy

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by459

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 670 citations.

PMID	Title	Journal	Year	In Papers	Source
42,910,047	Nicotinonitriles-based therapeutics as versatile pharmacophores in rational anticancer drug design.	RSC Adv	2026	https://conductscience.org/library/papers/42910047	PubMed
42,881,857	Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib.	J Clin Med	2026	https://conductscience.org/library/papers/42881857	PubMed
42,824,816	FGFR signaling and apoptotic regulation in cancer: links to immune evasion, therapeutic resistance, and treatment re-engagement.	Front Immunol	2026	https://conductscience.org/library/papers/42824816	PubMed
42,713,141	Fibroblast growth factor receptor 1 status discordance between primary breast tumours and lymph node metastases is associated with peripheral blood circulating tumour cell burden.	Contemp Oncol (Pozn)	2026	https://conductscience.org/library/papers/42713141	PubMed
42,686,986	NatD promotes glioblastoma progression through epigenetic activation of FGFR4 signalling.	Exp Mol Med	2026	https://conductscience.org/library/papers/42686986	PubMed
42,675,086	Discovery of a covalent FGFR2-selective inhibitor overcoming clinically-acquired resistance mutations.	Nat Commun	2026	https://conductscience.org/library/papers/42675086	PubMed
42,633,326	Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.	MedComm (2020)	2026	https://conductscience.org/library/papers/42633326	PubMed
42,589,248	Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial Translational Strategies.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42589248	PubMed
42,579,020	M2 macrophage-derived exosomal EHF transcriptionally activates FGFR1 to promote malignant phenotypes and glycolysis in NSCLC.	J Bioenerg Biomembr	2026	https://conductscience.org/library/papers/42579020	PubMed
42,510,988	Mutational Landscape of FGFR4 Across Malignancies: A Cross-Cancer Analysis of the AACR Project GENIE Database.	Curr Issues Mol Biol	2026	https://conductscience.org/library/papers/42510988	PubMed

1 to 10 of 459

See all 459 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28303906

GET https://conductscience.org/api/papers/v1/28303906/cited_by?page=2

API reference For AI assistants